Molecular conformation, receptor binding, and hormone action of natural and synthetic estrogens and antiestrogens.
The X-ray crystallographic structural determinations of synthetic estrogens and antiestrogens provide reliable information on the global minimum energy conformation of these molecules or a local minimum energy conformation that is within 1 or 2 kcal/mole of the global minimum. In favorable cases, state-of-the-art molecular mechanics calculations provide quantitative agreement with X-ray results and information on the relative energy of other local minimum energy conformations not observed crystallographically. Because the conformation of diethylstilbestrol (DES) observed in solvated crystals has an overall conformation and dipole moment more similar to estradiol it is the form more likely to bind to the receptor and produce hormone activity. Either phenol ring of DES can successfully mimic the estradiol A-ring in binding to the receptor. Indenestrol A (INDA) and indenestrol B (INDB) have nearly identical fully extended planar conformations. Either the alpha or gamma rings of these compounds may mimic the A ring of estradiol and compete for the estrogen receptor. Although there are eight distinct ways in which molecules of a racemic mixture of INDA or INDB can bind to the receptor, not all of them may be able to elicit a hormonal response. This may account for the reduced biological activity of the compounds despite their successful competition for receptor binding. The minimum energy conformations of Z-pseudodiethylstilbestrol (ZPD) and E-pseudodiethylstilbestrol (EPD) are bent in a fashion similar to that of indanestrol (INDC). These molecules have good binding affinity suggesting that the receptor does not require a flat molecule. Therefore these conformations would appear to be compatible with receptor binding, but only the Z isomer has an energetically allowed extended conformation that accounts for its observed biological activity relative to DES.
D004054:Diethylstilbestrol / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D045166:Estradiol Congeners / Q000378:metabolism / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000378:metabolism / Q000494:pharmacology*; D004967:Estrogens / Q000378:metabolism / Q000494:pharmacology*; D004968:Estrogens, Non-Steroidal / Q000378:metabolism / Q000494:pharmacology*; D007189:Indans / Q000494:pharmacology; D007192:Indenes / Q000494:pharmacology; D008968:Molecular Conformation; D011960:Receptors, Estrogen / Q000378:metabolism*; D013329:Structure-Activity Relationship; D013629:Tamoxifen / Q000494:pharmacology; D014961:X-Ray Diffraction
D045166:Estradiol Congeners; D004965:Estrogen Antagonists; D004967:Estrogens; D004968:Estrogens, Non-Steroidal; D007189:Indans; D007192:Indenes; D011960:Receptors, Estrogen; D013629:Tamoxifen; C013661:pseudodiethylstilbestrol; C047437:indenestrol; D004958:Estradiol; C047438:indanestrol; D004054:Diethylstilbestrol